Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Other Gross PP&E Adjustments (2019 - 2025)

BioNexus Gene Lab's Other Gross PP&E Adjustments history spans 7 years, with the latest figure at $2.4 million for Q3 2025.

  • For Q3 2025, Other Gross PP&E Adjustments rose 96.87% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $2.4 million, up 96.87%, while the annual FY2024 figure was $2.3 million, 1.59% up from the prior year.
  • Other Gross PP&E Adjustments for Q3 2025 was $2.4 million at BioNexus Gene Lab, up from $2.3 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $2.4 million in Q3 2025 and bottomed at -$55730.0 in Q4 2022.
  • The 5-year median for Other Gross PP&E Adjustments is $2.2 million (2022), against an average of $1.7 million.
  • The largest YoY upside for Other Gross PP&E Adjustments was 11102.29% in 2021 against a maximum downside of 180.89% in 2021.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $2.2 million in 2021, then tumbled by 102.57% to -$55730.0 in 2022, then soared by 4146.43% to $2.3 million in 2023, then grew by 1.59% to $2.3 million in 2024, then rose by 2.83% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Other Gross PP&E Adjustments are $2.4 million (Q3 2025), $2.3 million (Q2 2025), and $2.3 million (Q1 2025).